Mats Eriksson

10.6k total citations · 3 hit papers
135 papers, 7.2k citations indexed

About

Mats Eriksson is a scholar working on Surgery, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Mats Eriksson has authored 135 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Surgery, 30 papers in Molecular Biology and 29 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Mats Eriksson's work include Lipoproteins and Cardiovascular Health (54 papers), Cholesterol and Lipid Metabolism (31 papers) and Cancer, Lipids, and Metabolism (24 papers). Mats Eriksson is often cited by papers focused on Lipoproteins and Cardiovascular Health (54 papers), Cholesterol and Lipid Metabolism (31 papers) and Cancer, Lipids, and Metabolism (24 papers). Mats Eriksson collaborates with scholars based in Sweden, United States and United Kingdom. Mats Eriksson's co-authors include Bo Angelin, John J.P. Kastelein, Charles L. Shear, Bryan Brewer, James H. Revkin, Michel Komajda, David D. Waters, Philip J. Barter, Mark J. Caulfield and Marian R. Fisher and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Mats Eriksson

133 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Torcetrapib in Patients at High Risk for Coronary Events

2007 2.2k citations Mats Eriksson et al. profile →
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)

2014 281 citations Mats Eriksson et al. Journal of the American College of Cardiology profile →
Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study

2023 170 citations Kausik K. Ray, Aikaterini Bilitou et al. The Lancet Regional Health - Europe profile →

Peers

Countries citing papers authored by Mats Eriksson

Since Specialization

Citations

This map shows the geographic impact of Mats Eriksson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mats Eriksson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mats Eriksson more than expected).

Fields of papers citing papers by Mats Eriksson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mats Eriksson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mats Eriksson. The network helps show where Mats Eriksson may publish in the future.

Co-authorship network of co-authors of Mats Eriksson

This figure shows the co-authorship network connecting the top 25 collaborators of Mats Eriksson. A scholar is included among the top collaborators of Mats Eriksson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mats Eriksson. Mats Eriksson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study breakdown → 2023 ·The Lancet Regional Health - Europe ·Kausik K. Ray, (unknown), Aikaterini Bilitou, (unknown), Annie Burden, Carlos Aguíar, Marcello Arca, Derek Connolly, Mats Eriksson, Jean Ferrières, Ulrich Laufs, José María Mostaza, David Nanchen, Ernst Rietzschel, Timo Strandberg, Hermann Toplak, Frank L.J. Visseren, Alberico L. Catapano	170
2	Soat2 ties cholesterol metabolism to β-oxidation and glucose tolerance in male mice 2022 ·Oxford University Research Archive (ORA) (University of Oxford) ·Camilla Pramfalk, Ahmed Osman, Matteo Pedrelli, (unknown), Serge Luquet, R Denis, Maria Olin, (unknown), Lise‐Lotte Vedin, Knut R. Steffensen, Mikael Rydén, Leanne Hodson, Mats Eriksson, Paolo Parini	16
3	Generation of new hepatocyte-like in vitro models better resembling human lipid metabolism 2020 ·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids ·Camilla Pramfalk, Tomas Jakobsson, (unknown), (unknown), (unknown), (unknown), Maria Olin, Matteo Pedrelli, Mats Eriksson, Paolo Parini	5
4	[Acute flaccid myelitis amongst Swedish children with a possible link to an outbreak of enterovirus D68]. 2017 ·PubMed ·(unknown), Daniel Martín Muñoz, (unknown), Mia Brytting, Mats Eriksson	1
5	Hepatic ACAT2 Knock Down Increases ABCA1 and Modifies HDL Metabolism in Mice 2014 ·PLoS ONE ·Matteo Pedrelli, Padideh Davoodpour, Chiara Degirolamo, Monica Gomaraschi, Mark J. Graham, Alice Ossoli, Lilian Larsson, Laura Calabresi, Jan-Ακε Gustafsson, Knut R. Steffensen, Mats Eriksson, Paolo Parini	24
6	Atorvastatin Treatment Induces Uptake and Efflux Transporters in Human Liver 2013 ·Drug Metabolism and Disposition ·Linda Björkhem‐Bergman, (unknown), (unknown), Paolo Parini, Mats Eriksson, Anders Rane, Lena Ekström	13
7	SHORT-TERM AND LONG-TERM EFFECTS OF PITAVASTATIN AND SIMVASTATIN ON FASTING PLASMA GLUCOSE IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AND ≥2 RISK FACTORS FOR CORONARY HEART DISEASE 2012 ·Journal of the American College of Cardiology ·(unknown), Mats Eriksson, Neil Hounslow, Craig A. Sponseller	4
8	Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial 2011 ·Advances in Therapy ·Mats Eriksson, Dragos Budinski, Neil Hounslow	29
9	Dynamics of human adipose lipid turnover in health and metabolic disease 2011 ·Nature ·Peter Arner, Samuel Bernard, Mehran Salehpour, Göran Possnert, Jakob Liebl, Peter Steier, Bruce A. Buchholz, Mats Eriksson, Hans Hauner, Thomas Skurk, Mikael Rydén, Keith N. Frayn, Kirsty L. Spalding	286
10	Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe 2010 ·Current Opinion in Lipidology ·Gilbert R. Thompson, Alberico L. Catapano, Samir Saheb, (unknown), Mahmoud Barbir, Mats Eriksson, Bernhard Paulweber, Eric J.G. Sijbrands, Anton F. H. Stalenhoef, Klaus G. Parhofer	83
11	The Circulating Metabolic Regulator FGF21 Is Induced by Prolonged Fasting and PPARα Activation in Man 2008 ·Cell Metabolism ·Cecilia Gälman, (unknown), Alexei Kharitonenkov, Holly A. Bina, Mats Eriksson, Ingiäld Hafström, Maria Dahlin, Per Åmark, Bo Angelin, Mats Rudling	429
12	Cholesterol regulates ACAT2 gene expression and enzyme activity in human hepatoma cells 2007 ·Biochemical and Biophysical Research Communications ·Camilla Pramfalk, Bo Angelin, Mats Eriksson, Paolo Parini	22
13	Control of ACAT2 liver expression by HNF1 2005 ·Journal of Lipid Research ·Camilla Pramfalk, Matthew A. Davis, Mats Eriksson, Lawrence L. Rudel, Paolo Parini	30
14	Studies of drug binding to plasma proteins using a variant of equilibrium dialysis 2005 ·Journal of Pharmaceutical and Biomedical Analysis ·Mats Eriksson, Johan Gabrielsson, Lars B. Nilsson	26
15	Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment 2004 ·Journal of Internal Medicine ·Suzanne Lind, Anders Olsson, Mats Eriksson, Mats Rudling, Gösta Eggertsen, B. Angelin	45
16	Kinetic analysis of LDL apoB transport and metabolism in non-steady states 2000 ·Control and Cybernetics ·Andrzej Weryński, Zbigniew Nahorski, Bo Angelin, Lars Berglund, Mats Eriksson	1
17	The effect of plasma low density lipoprotein apheresis on the hepatic secretion of biliary lipids in humans 1997 ·Gut ·Carl-Gustaf Hillebrant, Björn Nyberg, Kurt Einarsson, Mats Eriksson	23
18	Cholecystokinin peptides in cerebrospinal fluid: a study in healthy male subjects 1997 ·Regulatory Peptides ·(unknown), (unknown), Mats Eriksson, G. Ali Qureshi, Stefan Sjöberg, Conny Nordin	8
19	Metabolism of plasma low density lipoproteins in familial combined hyperlipidaemia: effect of acipimox therapy 1992 ·Journal of Internal Medicine ·S Ericsson, Mats Eriksson, Lars Berglund, Bo Angelin	6
20	Lipid lowering in severe familial hypercholesterolaemia: efficacy and safety of a new regenerating system for selective apheresis of apolipoprotein B‐containing lipoproteins 1989 ·Journal of Internal Medicine ·Mats Eriksson, (unknown), Lars Berglund, B. M. T. Lantz, Bo Angelin	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact